AYTU

AYTU BIOPHARMA, INC. - 10-K Summary

Business Context and Reporting Period

Company: AYTU BIOPHARMA, INC. (AYTU)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2025
Business Overview: Aytu is a pharmaceutical company focused on central nervous system (CNS) diseases. The company operates as a single segment following the divestiture of its Consumer Health business in Q1 2025. Its portfolio consists of the ADHD Portfolio (Adzenys, Cotempla), the Pediatric Portfolio (Karbinal, Poly-Vi-Flor, Tri-Vi-Flor), and the newly acquired commercialization rights for EXXUA (gepirone) for Major Depressive Disorder (MDD), with a launch anticipated in Q4 2025.

Key Financial Metrics

Note: Total Debt includes $13.0 million Term Loan and $9.1 million Revolving Credit Facility outstanding as of June 30, 2025.

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 2% to $66.4 million, driven by a 20% increase in the Pediatric Portfolio ($8.8 million) offset by a slight decline in the ADHD Portfolio ($57.6 million).
• Margin Compression: Gross margin decreased from 75% to 69% primarily due to the sell-through of self-manufactured ADHD inventory carrying higher fixed costs.
• Impairment Charges: The company recorded $8.3 million in impairment expense related to intangible assets (Karbinal and Poly-Vi-Flor) as it shifted focus to EXXUA and the ADHD portfolio. No impairment was recorded in 2024.
• Discontinued Operations: The Consumer Health business was divested in Q1 2025. Results are reported as discontinued operations, contributing a net income of $0.6 million for the period, compared to a loss of $3.3 million in 2024.
• Financing Activity: In June 2025, the company raised $14.8 million in net proceeds from a public offering of common stock and prefunded warrants. Additionally, the Eclipse Term Loan was amended to $13.0 million, and the Revolving Credit Facility was drawn up to $9.1 million.

Guidance, Outlook, and Risks

• Strategic Focus: Management is prioritizing the launch of EXXUA in Q4 2025 as a major growth catalyst. Active clinical development programs (e.g., AR101) have been indefinitely suspended or divested to focus on commercialization.
• Profitability Outlook: The company expects to continue incurring significant expenses but anticipates achieving profitability through the growth of its commercial business. It has not established ongoing net revenue sufficient to cover operating costs.
• Liquidity: As of June 30, 2025, cash and cash equivalents totaled $31.0 million. The company may need to raise additional funding to support operations and the EXXUA launch.
• Key Risks:
  • Generic Competition: Adzenys faces generic entry from Actavis (Teva) starting September 1, 2025, and Cotempla from Teva starting July 1, 2026. A Paragraph IV lawsuit against Granules regarding Adzenys is ongoing.
  • Customer Concentration: Four customers accounted for 85% of gross revenue and 89% of gross accounts receivable in 2025.
  • Debt Covenants: The Eclipse Agreement imposes financial covenants and restrictions on operating flexibility. Failure to comply could result in an event of default.
  • Regulatory: ADHD products are Schedule II controlled substances, subject to strict DEA regulations and quota limitations.

Investor Verification Checklist

• EXXUA Launch Timeline: Verify the actual launch date and initial sales performance of EXXUA in Q4 2025.
• Generic Impact: Monitor the impact of the September 2025 generic entry for Adzenys on revenue and market share.
• Liquidity Runway: Assess whether the $31 million cash balance and revolving credit facility are sufficient to fund operations until profitability is achieved.
• Customer Concentration: Review the stability of the top four customers representing 85% of revenue.
• Debt Compliance: Confirm continued compliance with Eclipse Agreement financial covenants.